NASDAQ: AKBAAkebia Therapeutics Inc Stock
$0.87-0.05 (-5.43%)
Updated Jun 10, 2026
AKBA Price
$0.87
Fair Value Price
N/A
Market Cap
$234.19M
52 Week Low
$0.82
52 Week High
$4.08
P/E
-10.91x
P/B
8.55x
P/S
1.6x
PEG
N/A
Dividend Yield
N/A
Revenue
$232.40M
Earnings
-$20.51M
Gross Margin
81%
Operating Margin
1.01%
Profit Margin
-8.8%
Debt to Equity
12.24
Operating Cash Flow
$60M
Beta
1.47
Next Earnings
Aug 6, 2026
Ex-Dividend
N/A
Next Dividend
N/A
AKBA Overview
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AKBA's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
AKBA
Ranked#320 of 462
Ranked#320 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $229.63 | A | |
| $52.58 | A | |
| $15.66 | A |
Be the first to know about important AKBA news, forecast changes, insider trades & much more!
AKBA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AKBA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AKBA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AKBA is poor value based on its book value relative to its share price (8.55x), compared to the US Biotechnology industry average (4.71x)
P/B vs Industry Valuation
AKBA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more AKBA due diligence checks available for Premium users.
Valuation
AKBA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-10.91x
Industry
18.33x
Market
14.77x
AKBA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
8.55x
Industry
4.71x
AKBA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AKBA's financial health
Profit margin
Revenue
$53.5M
Net Income
-$9.1M
Profit Margin
-16.9%
AKBA's Earnings (EBIT) of $2.34M... subscribe to Premium to read more.
Interest Coverage Financials
AKBA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$362.5M
Liabilities
$335.1M
Debt to equity
12.24
AKBA's short-term assets ($243.48M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AKBA's short-term assets ($243.48M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AKBA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
AKBA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$21.2M
Investing
-$62.0k
Financing
-$926.0k
AKBA's operating cash flow ($60.37M)... subscribe to Premium to read more.
Debt Coverage Financials
AKBA vs Biotech Stocks
Akebia Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.